Optimizing In Vivo Models for Preclinical Drug Development
Effective preclinical drug development hinges on the deployment of robust in vivo models that accurately recapitulate human disease and response to therapy. Optimizing these models involves a multifaceted approach, encompassing careful evaluation of species selection, genetic background, disease pre